Larimar Therapeutics (LRMR) has had a few hiccups since I last wrote about this biotech. This was in a prior Seeking Alpha article I wrote entitled "Larimar: Friedreich's Ataxia Drug With Significant ...
Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich's ataxia and uncertainty about its functional benefits. The stock has dropped over 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback